ArticleBritish journal of clinical pharmacology2013
What can we learn from parents about enhancing participation in pharmacovigilance?
Article in British journal of clinical pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Factors that influence patient and public adverse drug reaction reporting: a systematic review using the theoretical domains framework.International journal of clinical pharmacy · 2023Pooled it
- Factors affecting patient reporting of adverse drug reactions: a systematic review.British journal of clinical pharmacology · 2017Pooled it
- The value of patient reporting to the pharmacovigilance system: a systematic review.British journal of clinical pharmacology · 2017Pooled it
- Strengthening pharmacovigilance through patient reporting: a scoping review of awareness, barriers, and facilitators.Journal of pharmaceutical policy and practice · 2026Review
- Barriers and enablers of adverse drug event reporting in South Africa: a cross-sectional survey of medicine users.BMC public health · 2025Article
- Part 1 - imidazolines and the changing face of nasal decongestants.Frontiers in pharmacology · 2025Review
- Factors Associated with the Public's Intention to Report Adverse Drug Reactions to Community Pharmacists in the Makkah Region of Saudi Arabia: An Application of the Theory of Planned Behavior.Patient preference and adherence · 2024Article
- Perceptions, practices and barriers to reporting of adverse drug reactions among HIV infected patients and their doctors in 3 public sector hospitals of the Ethekwini Metropolitan, Kwa-Zulu Natal: a cross sectional and retrospective analysis.BMC health services research · 2022Article
- Parental reporting of adverse drug reactions in South Africa: An online survey.African journal of primary health care & family medicine · 2021Article
- Patients' experiences on adverse drug reactions reporting: a qualitative study.European journal of clinical pharmacology · 2020Article
- Consumer opinions on adverse events associated with medicines and vaccines.Patient preference and adherence · 2018Article
- Patient Reporting in the EU: Analysis of EudraVigilance Data.Drug safety · 2017Article
- ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems.Drug safety · 2015Review
- Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance.SpringerPlus · 2014Review
- Consumer reporting of adverse events following immunization (AEFI): identifying predictors of reporting an AEFI.Human vaccines & immunotherapeutics · 2014Article
- Pediatric clinical pharmacology: an introduction to a series of educational papers.European journal of pediatrics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimsTo investigate parents' views and experiences of direct reporting of a suspected ADR in their child.
methodsWe audio-recorded semi-structured qualitative interviews with parents of children with suspected ADRs. Our sample included parents with (n = 17) and without (n = 27) previous experience of submitting a Yellow Card.
resultsParents in both groups described poor awareness of the Yellow Card Scheme. Parents who had participated in the Yellow Card Scheme were generally happy to report their child's ADR via the Scheme and valued the opportunity to report concerns independently of health practitioners. They expressed motivations for reporting that have not previously been described linked to the parental role, including how registering a concern about a medicine helped to resolve uncomfortable feelings about their child's ADR. Parents who had not previously submitted a Yellow Card expressed uncertainty about the legitimacy of their involvement in reporting and doubts about the value of the information that they could provide.
conclusionPromoting wider participation in pharmacovigilance schemes will depend on raising public awareness. Additionally, our findings point to the need to empower lay people to submitting reports and to reassure them about the value of their reports.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.